Inhibikase Therapeutics IKT
NASDAQ IKT
$1.61 -0.05 (-3.01%)
As of: Oct 22, 2026 · 11:55 AM EDT

Inhibikase Therapeutics (IKT) Other Non-Current Assets (2021 - 2026)

Updated

Inhibikase Therapeutics (IKT) reported Other Non-Current Assets of $1 million for Q2 2026, up 225.3% from $307,373 a year earlier and unchanged from the prior quarter.

Analysis

Inhibikase Therapeutics (IKT) Other Non-Current Assets (2021 - 2026) Analysis & Trends

Dating back to Q1 2021, Inhibikase Therapeutics' Other Non-Current Assets record includes 8 quarters.

  • By year, Other Non-Current Assets came in at $147,445 in FY2023.
  • Per Business Quant data, the three quarters before Q2 2026 came in at $1 million (Q1 2026), $1 million (Q4 2025) and $1 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Eli Lilly 1,170.86 Bn 1,139.45 Bn 19.71 Bn 7.48 Bn
2 Johnson & Johnson 639.81 Bn 558.34 Bn 17.26 Bn 14.27 Bn
3 AbbVie 501.68 Bn 474.79 Bn 12.70 Bn 10.73 Bn
4 Merck 374.79 Bn 329.16 Bn 12.21 Bn 19.60 Bn
5 Novartis Ag 302.69 Bn 266.68 Bn 11.24 Bn 5.93 Bn
6 Astrazeneca 268.27 Bn 241.96 Bn 12.86 Bn -
7 Amgen 242.43 Bn 197.83 Bn 7.24 Bn 12.98 Bn
8 Gilead Sciences 193.38 Bn 167.58 Bn 6.22 Bn 4.75 Bn
9 Pfizer 172.45 Bn 119.10 Bn 10.94 Bn 9.94 Bn
10 Inhibikase Therapeutics 280.19 Mn -305.29 Mn - 1.29 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.29 Mn
Mar 31, 2026 1.16 Mn
Dec 31, 2025 1.10 Mn
Sep 30, 2025 1.44 Mn
Jun 30, 2025 307,373.00
Sep 30, 2024 553,318.00
Dec 31, 2023 147,445.00
Mar 31, 2021 2,783.00
API Access

Inhibikase Therapeutics Other Non-Current Assets API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-current-assets&ticker=IKT&period=max&api_key=YOUR_API_KEY